NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY. (17th June 2021) - Ansell, S. M.; Bröckelmann, P. J.; von Keudell, G.; Lee, H. J.; Santoro, A.; Zinzani, P. L.; Collins, G. P.; Cohen, J. B.; De Boer, J. P.; Kuruvilla, J.; Savage, K. J.; Trneny, M.; et al.